Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces Boulardii CNCM I-745 in Patients with Erythema Migrans Undergoing Antibiotic Therapy
NCT06451913Phase 4Recruiting
- Sponsor
- Biocodex
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in antibiotic-associated diarrhea (AAD) comparing Amoxicillin + S. boulardii with Amoxicillin + Placebo (2 arms). Primary endpoint: Effect of Saccharomyces boulardii CNCM I-745 on gut microbiota at Day 21. Started Jul 2025; status: recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on NCT06451913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451913.